Scientific innovation leading to the restoration, preservation, and improvement of patient vision
Amber Ophthalmics is a clinical stage biopharmaceutical company formed in 2020, focused on driving novel therapeutics for rare anterior segment ophthalmic diseases.
Proven leadership team brings experience in multiple therapeutic areas and novel modalties, ensuring innovation translates to patient benefit
Driving lead clinical candidate, NEXAGON for the treatment of persistent corneal epithelial defects (PCED)
CORNEAL SURFACE DISEASE
Corneal surface disease encompasses a wide variety of conditions affecting the ocular surface. These conditions include dry eye disease, blepharitis, meibomian gland dysfunction, immunologic disorders and persistent corneal epithelial defects. (1)
PERSISTENT CORNEAL EPITHELIAL DEFECT (PCED)
PCED is a rare, progressive disease defined as prolonged loss of the corneal epithelium, caused by a variety of underlying etiologies. (2)
Over 100,000 patients in the United States are diagnosed annually, with as many as an estimated 50% progressing to corneal melt, the final stage before perforation, despite treatment. (3,4)
Standard of care (SOC) can include lubrication and therapeutic contact lens, with refractory patients receiving autologous serum drops and ultimately, surgical intervention. There is no FDA approved treatment for PCED. (2)
NEXAGON (LUFEPIRSEN OPHTHALMIC GEL)
Unmet Medical Need
Despite standard of care, patients remain at risk for corneal transplant or vision loss
Underserved >$1B market (3)
Proprietary MOA that addresses the common underlying pathology of PCED
Differentiated Product Profile
NEXAGON recognized as a potential paradigm shift to current therapy
NEX-PED-005 Clinical Study:
PCED secondary to chem./therm. injury
AMB-01-006 Clinical Study:
Amber Ophthalmics is positioned
for continued growth through
program acquisition, in-licensing
and partnering of
development stage assets.
Please contact us to find out more.
Amber Ophthalmics is located in sunny San Diego! Please contact us using the link below. We look forward to hearing from you.
Lim L, Lim EWL. Therapeutic Contact Lenses in the Treatment of Corneal and Ocular Surface Diseases-A Review. Asia Pac J Ophthalmol (Phila). 2020 Dec;9(6):524-532.
Golhait P, Peseyie R. Persistent Epithelial Defect. In: StatPearls. StatPearls Publishing, Treasure Island (FL); 2021. PMID: 34424633
DelveInsight, Persistent Epithelial Defects (PED) Market Insights, Epidemiology and Market Forecast - 2030; (2020)
Guidehouse Independent US PED Epidemiology Refresh (2021)